Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Report

Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Market Research Report (2017-2028)

  • POSTDATE：Nov 09, 2022
  • PAGES：201
  • REPORT CODE：GMM1358632
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Human Immunodeficiency Virus (HIV)-1 Therapeutics industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions along with the strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    Please note that the figures and tables shown in the sample are just for the purpose of demonstration, which may differ from those in the final report.

    Competitive Landscape:

    • Bristol-Myers Squibb Company (US)

    • Cipla Inc (India)

    • Merck & Co Inc (US)

    • Genentech Inc (US)

    • Boehringer Ingelheim GmbH (Germany)

    • AbbVie Inc(US)

    Region:

    • China

    • North America

    • Europe

    • APAC

    • Latin America, Middle East and Africa

    Type:

    • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)

    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

    • Entry and Fusion Inhibitors

    • Protease Inhibitors (PIs)

    • Integrase Inhibitors

    • Coreceptor Antagonists

    Application:

    • Hospitals

    • Clinics

    • Labs

  • Table of Content

    Chapter 1 Industry Overview & Development Status in Global and China Market

    • 1.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Overview

      • 1.1.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Scope and Market Segments

      • 1.1.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Characteristics

      • 1.1.3 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

      • 1.1.4 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Value and Growth Rate (2017-2028)

    • 1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate by Type (2017-2028)

      • 1.2.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)

      • 1.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

      • 1.2.3 Entry and Fusion Inhibitors

      • 1.2.4 Protease Inhibitors (PIs)

      • 1.2.5 Integrase Inhibitors

      • 1.2.6 Coreceptor Antagonists

    • 1.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate by Application (2017-2028)

      • 1.3.1 Hospitals

      • 1.3.2 Clinics

      • 1.3.3 Labs

    • 1.4 Market Analysis by Region

      • 1.4.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.4 Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • 1.5 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

      • 1.5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

    • 1.6 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Price, Sales Value (2017-2028)

      • 1.6.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Price, Sales Value (2017-2028)

    Chapter 2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Challenges and Restraints

      • 2.1.2 Opportunities and Potentialities

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape

      • 2.2.1 Market Concentration Rate Analysis

      • 2.2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Porter's Five Forces Model Analysis

      • 2.2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry PEST Analysis

    • 2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Chain Analysis

      • 2.3.1 Raw Material Supplies

      • 2.3.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Downstream Market Analysis

      • 2.3.3 Upstream and Downstream Impacts on Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry

    Chapter 3 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Manufacturer

    • 3.1 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Market Share, by Manufacturer (2021&2022)

      • 3.1.1 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Manufacturer (2021&2022)

      • 3.1.2 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value, by Manufacturer (2021&2022)

      • 3.1.3 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share, by Manufacturer (2021&2022)

    • 3.2 SWOT Analysis on Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Top 3 Players

    Chapter 4 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Type (2017-2028)

    • 4.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Trend, by Type

    • 4.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value, Market Share and Price Trend, by Type

      • 4.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Market Share, by Type (2017-2028)

      • 4.2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Market Share, by Type (2017-2028)

      • 4.2.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Price Trend, by Type (2017-2028)

    • 4.3 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value, Market Share and Price Trend, by Type

      • 4.3.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Market Share, by Type (2017-2028)

      • 4.3.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Market Share, by Type (2017-2028)

      • 4.3.3 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Price Trend, by Type (2017-2028)

    Chapter 5 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Application (2017-2028)

    • 5.1 Downstream Market Overview

    • 5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Market Share, by Application

      • 5.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Market Share, by Application (2017-2028)

      • 5.2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Market Share, by Application (2017-2028)

    • 5.3 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Market Share, by Application

      • 5.3.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Market Share, by Application (2017-2028)

      • 5.3.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Market Share, by Application (2017-2028)

    Chapter 6 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export, by Region (2017-2022)

    • 6.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • 6.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • 6.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • 6.4 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • 6.5 Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    Chapter 7 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis

    • 7.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Type

    • 7.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Application

    • 7.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis and Forecast, by Country

      • 7.3.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 7.3.2 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 7.3.3 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 8 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis

    • 8.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Type

    • 8.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Application

    • 8.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis and Forecast, by Country

      • 8.3.1 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.2 UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.3 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.4 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.5 Nordic Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.6 Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.7 Belgium Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.8 Poland Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.9 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.10 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 9 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis

    • 9.1 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Type

    • 9.2 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Application

    • 9.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis and Forecast, by Country

      • 9.3.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.2 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.3 Australia and New Zealand Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.4 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.5 ASEAN Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.6 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 10 Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis

    • 10.1 Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Type

    • 10.2 Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Application

    • 10.3 Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis and Forecast, by Country

      • 10.3.1 GCC Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.2 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.3 Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.4 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.5 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 11 Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Company Profiles

      • 11.1 Bristol-Myers Squibb Company (US)

        • 11.1.1 Bristol-Myers Squibb Company (US) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.1.2 Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Profiles, Application and Specification

        • 11.1.3 Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.2 Cipla Inc (India)

        • 11.2.1 Cipla Inc (India) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.2.2 Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Profiles, Application and Specification

        • 11.2.3 Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.3 Merck & Co Inc (US)

        • 11.3.1 Merck & Co Inc (US) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.3.2 Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Profiles, Application and Specification

        • 11.3.3 Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.4 Genentech Inc (US)

        • 11.4.1 Genentech Inc (US) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.4.2 Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Profiles, Application and Specification

        • 11.4.3 Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.5 Boehringer Ingelheim GmbH (Germany)

        • 11.5.1 Boehringer Ingelheim GmbH (Germany) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.5.2 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Profiles, Application and Specification

        • 11.5.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.6 AbbVie Inc(US)

        • 11.6.1 AbbVie Inc(US) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.6.2 AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Profiles, Application and Specification

        • 11.6.3 AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    Chapter 12 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Investment Prospect and Risk Assessment

    • 12.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Investment Prospect Assessment

      • 12.1.1 Investment Opportunities in Segmented Markets

      • 12.1.2 Investment Opportunities in Regional Markets

      • 12.1.3 Investment Opportunities in Subdivided Industries

    • 12.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Investment Risk Assessment

      • 12.2.1 Competitive Risk Analysis

      • 12.2.2 Technology Risk Analysis

      • 12.2.3 Policies and Enterprise System Risk Analysis

    List of Tables and Figures

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Value and Growth Rate (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Value and Growth Rate (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Entry and Fusion Inhibitors (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Protease Inhibitors (PIs) (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Integrase Inhibitors (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Coreceptor Antagonists (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Hospitals (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Clinics (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Growth Rate of Labs (2017-2028)

    • Figure North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • Figure Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • Figure APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • Figure Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Price, Sales Value (2017-2028)

    • Figure Porter's Five Forces Model Analysis

    • Figure Industry PEST Analysis

    • Table Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Manufacturer (2021&2022)

    • Table Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value, by Manufacturer (2021&2022)

    • Table Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share, by Manufacturer (2021&2022)

    • Figure Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share, by Manufacturer in 2021

    • Figure Global and China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share, by Manufacturer in 2022

    • Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Type (2017-2028)

    • Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value, by Type (2017-2028)

    • Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value Share, by Type (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Price Trend, by Type (2017-2028)

    • Table China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Type (2017-2028)

    • Table China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value, by Type (2017-2028)

    • Table China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value Share, by Type (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Price Trend, by Type (2017-2028)

    • Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Application (2017-2028)

    • Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value, by Application (2017-2028)

    • Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value Share, by Application (2017-2028)

    • Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value Share, by Application (2017-2028)

    • Table China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Application (2017-2028)

    • Table China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Table China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value, by Application (2017-2028)

    • Table China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value Share, by Application (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value Share, by Application (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Figure North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Figure Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Figure APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Figure Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Table North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Type (2017-2028)

    • Table North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Application (2017-2028)

    • Table North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Table Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Type (2017-2028)

    • Table Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Application (2017-2028)

    • Table Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure France Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure France Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Nordic Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Nordic Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Belgium Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Belgium Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Poland Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Poland Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Table APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Type (2017-2028)

    • Table APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Application (2017-2028)

    • Table APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Australia and New Zealand Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Australia and New Zealand Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure India Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure India Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure ASEAN Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure ASEAN Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Table Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Type (2017-2028)

    • Table Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, by Application (2017-2028)

    • Table Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure Latin America, Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure GCC Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure GCC Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Value and Growth Rate (2017-2028)

    • Table Bristol-Myers Squibb Company (US) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Bristol-Myers Squibb Company (US) Product Profiles, Application and Specification

    • Table Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Cipla Inc (India) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Cipla Inc (India) Product Profiles, Application and Specification

    • Table Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Merck & Co Inc (US) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Merck & Co Inc (US) Product Profiles, Application and Specification

    • Table Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Genentech Inc (US) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Genentech Inc (US) Product Profiles, Application and Specification

    • Table Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Boehringer Ingelheim GmbH (Germany) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Boehringer Ingelheim GmbH (Germany) Product Profiles, Application and Specification

    • Table Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table AbbVie Inc(US) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table AbbVie Inc(US) Product Profiles, Application and Specification

    • Table AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US